Abstract
Few selective cyclooxygenase-1 (COX-1) inhibitors have been described up to now, although recent studies underlined the involvement of COX-1 in the carcinogenesis, pathogenesis of neuroinflammation, cardiovascular diseases and pain. Among the known COX-1 inhibitors none proved to be a good drug candidate, with the exception of mofezolac, that is clinically used as an analgesic drug. New selective inhibitors were very often discovered as a minor achievement during SAR investigations to discover selective COX-2 inhibitors (COXIBs). After a recognition of the new COX-1 inhibitors synthesized in the last five years, it was attempted to draw, for each chemical class, a structure which might highlight the determinant molecular features able to switch the selectivity towards the COX-1 isoform. Overall, this review could constitute a tool to a better design of novel selective COX-1 inhibitors, to be used in a disease theranostic approach targeting COX-1.
Keywords: Cyclooxygenase (COX)-1, COX-2, structure-activity relationship(SAR), diarylheterocycles, benzanilides, arylpropanoic acids, stilbenes, NSAIDs.
Current Medicinal Chemistry
Title:Update on SAR Studies Toward New COX-1 Selective Inhibitors
Volume: 22 Issue: 37
Author(s): Paola Vitale, Antonio Scilimati and Maria Grazia Perrone
Affiliation:
Keywords: Cyclooxygenase (COX)-1, COX-2, structure-activity relationship(SAR), diarylheterocycles, benzanilides, arylpropanoic acids, stilbenes, NSAIDs.
Abstract: Few selective cyclooxygenase-1 (COX-1) inhibitors have been described up to now, although recent studies underlined the involvement of COX-1 in the carcinogenesis, pathogenesis of neuroinflammation, cardiovascular diseases and pain. Among the known COX-1 inhibitors none proved to be a good drug candidate, with the exception of mofezolac, that is clinically used as an analgesic drug. New selective inhibitors were very often discovered as a minor achievement during SAR investigations to discover selective COX-2 inhibitors (COXIBs). After a recognition of the new COX-1 inhibitors synthesized in the last five years, it was attempted to draw, for each chemical class, a structure which might highlight the determinant molecular features able to switch the selectivity towards the COX-1 isoform. Overall, this review could constitute a tool to a better design of novel selective COX-1 inhibitors, to be used in a disease theranostic approach targeting COX-1.
Export Options
About this article
Cite this article as:
Vitale Paola, Scilimati Antonio and Perrone Grazia Maria, Update on SAR Studies Toward New COX-1 Selective Inhibitors, Current Medicinal Chemistry 2015; 22 (37) . https://dx.doi.org/10.2174/0929867322666151029104717
DOI https://dx.doi.org/10.2174/0929867322666151029104717 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Tyrosine Kinase Receptors in Hepatocellular Carcinoma
Current Cancer Drug Targets Indolo[2,3-a]quinolizidines and Derivatives: Bioactivity and Asymmetric Synthesis
Current Pharmaceutical Design TNF-α Polymorphisms and Maternal Depression in a Mexican Mestizo Population
CNS & Neurological Disorders - Drug Targets Different Types of Cell Death in Organismal Aging and Longevity: State of the Art and Possible Systems Biology Approach
Current Pharmaceutical Design Emerging Synergisms Between Drugs and Physiologically-Patterned Weak Magnetic Fields: Implications for Neuropharmacology and the Human Population in the Twenty-First Century
Current Neuropharmacology NGAL is a Precocious Marker of Therapeutic Response
Current Pharmaceutical Design Recent Patents Relating To HCV Molecules Like Putative Targets For Therapeutic Intervention
Recent Patents on DNA & Gene Sequences Emerging Targets in Neurodegeneration: New Opportunities for Alzheimer's Disease Treatment?
Current Topics in Medicinal Chemistry Preface
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders Triplex-Forming Oligonucleotides - Sequence-Specific DNA Ligands as Tools for Gene Inhibition and for Modulation of DNA-Associated Functions
Current Drug Targets The Role of Neutrophils and TH17 Cells in the Immunopathology of Severe Asthmax
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets A Review of Calcium Pyrophosphate Deposition (CPPD)
Current Medical Imaging Therapeutic HIV Vaccines
Current Topics in Medicinal Chemistry Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets